Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 76 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 76 shares of the business’s stock in a transaction on Monday, October 26th. The stock was sold at an average price of $198.13, for a total value of $15,057.88. Following the sale, the executive vice president directly owned 19,568 shares in the company, valued at $3,877,007.84. This trade represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, September 28th, Michael Feld sold 76 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $183.70, for a total value of $13,961.20.
• On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $188.49, for a total value of $31,100.85.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $195.10 on Wednesday. The business’s 50-day moving average price is $185.89 and its 200 day moving average price is $170.36. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $200.47.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the company posted $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Maryland Capital Advisors Inc. boosted its stake in shares of Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 139 shares during the period. Trifecta Capital Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 59.0% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 62 shares in the last quarter. Meeder Asset Management Inc. increased its stake in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the last quarter. Main Street Group LTD acquired a new position in shares of Becton, Dickinson and Company in the first quarter worth $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth $29,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BDX has been the subject of several research analyst reports. TD Cowen upped their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research report on Thursday, August 13th. Jefferies Financial Group reiterated a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Barclays began coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an “underweight” rating and a $165.00 target price on the stock. Finally, Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.